Journal articles on the topic 'HBeAg Seroconversion'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'HBeAg Seroconversion.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Li, Guo-Jun, Yi-Qi Yu, Shao-Long Chen, Ping Fan, Ling-Yun Shao, Jia-Zhen Chen, Chang-Shui Li, et al. "Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment." Antimicrobial Agents and Chemotherapy 59, no. 7 (May 4, 2015): 4121–28. http://dx.doi.org/10.1128/aac.00249-15.
Full textHu, Yao-ren, Hua-dong Yan, Guo-sheng Gao, Cheng-liang Zhu, and Ji-fang Cheng. "Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α." Infection International 3, no. 1 (March 1, 2014): 10–15. http://dx.doi.org/10.1515/ii-2017-0067.
Full textKessler, Harald H., Sabine Preininger, Evelyn Stelzl, Elisabeth Daghofer, Brigitte I. Santner, Egon Marth, Herwig Lackner, and Rudolf E. Stauber. "Identification of Different States of Hepatitis B Virus Infection with a Quantitative PCR Assay." Clinical Diagnostic Laboratory Immunology 7, no. 2 (March 1, 2000): 298–300. http://dx.doi.org/10.1128/cdli.7.2.298-300.2000.
Full textSbarigia, Urbano, Talitha Vincken, Peter Wigfield, Mahmoud Hashim, Bart Heeg, and Maarten Postma. "A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients." Journal of Comparative Effectiveness Research 9, no. 15 (October 2020): 1051–65. http://dx.doi.org/10.2217/cer-2020-0068.
Full textHees, Chi, Hansen, Bourgeois, Vlierberghe, Sersté, Francque, et al. "Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion." Viruses 11, no. 8 (July 26, 2019): 687. http://dx.doi.org/10.3390/v11080687.
Full textHoa, Pham Thi Le, Nguyen Tien Huy, Le The Thu, Cao Ngoc Nga, Kazuhiko Nakao, Katsumi Eguchi, Nguyen Huu Chi, Bui Huu Hoang, and Kenji Hirayama. "Randomized Controlled Study Investigating Viral Suppression and Serological Response following Pre-S1/Pre-S2/S Vaccine Therapy Combined with Lamivudine Treatment in HBeAg-Positive Patients with Chronic Hepatitis B." Antimicrobial Agents and Chemotherapy 53, no. 12 (September 21, 2009): 5134–40. http://dx.doi.org/10.1128/aac.00276-09.
Full textVilleneuve, Jean-Pierre, and Bernard Willems. "Treatment of Chronic Hepatitis B with Interferon: Long Term Follow-Up." Canadian Journal of Gastroenterology 10, no. 1 (1996): 21–25. http://dx.doi.org/10.1155/1996/683012.
Full textEcin, Seval Müzeyyen, Nursel Çalık Başaran, and Murat Aladağ. "Evaluation of the Effectiveness of Tenofovir in Chronic Hepatitis B Patients." Acta Medica 51, no. 1 (March 17, 2020): 9–14. http://dx.doi.org/10.32552/0.actamedica.423.
Full textLee, Hyun Woong, Jae-Cheol Kwon, In Soo Oh, Hye Young Chang, Young Joo Cha, Ik-Seong Choi, and Hyung Joon Kim. "Prolonged Entecavir Therapy Is Not Effective for HBeAg Seroconversion in Treatment-Naive Chronic Hepatitis B Patients with a Partial Virological Response." Antimicrobial Agents and Chemotherapy 59, no. 9 (June 22, 2015): 5348–56. http://dx.doi.org/10.1128/aac.01017-15.
Full textKIMURA, Akihiko, Masayoshi KAGE, Ken YUGE, and Eiichiro ONO. "HBsAg positive chronic hepatitis in children : Seroconversion from HBeAg to anti-HBe and HBcAg in liver." Kanzo 27, no. 10 (1986): 1363–70. http://dx.doi.org/10.2957/kanzo.27.1363.
Full textHe, Qing, Qi-yuan Tang, Xiao-hua Le, De-liang Lv, Xiang-mei Zhang, Fei-jian Ao, Yi-min Tang, Shan Huang, John Nunnari, and Gui-lin Yang. "The Relationship between Intrahepatic Distribution of Hepatitis B Virus Core Antigen and Serum ALT, HBV DNA Levels and HBeAg Status." Infection International 1, no. 2 (June 1, 2012): 84–90. http://dx.doi.org/10.1515/ii-2017-0013.
Full text&NA;. "HBeAg seroconversion and longterm outcome with interferon-??" Inpharma Weekly &NA;, no. 1040 (June 1996): 12. http://dx.doi.org/10.2165/00128413-199610400-00024.
Full textMa, Hui, Rui-feng Yang, and Lai Wei. "Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients." Journal of Gastroenterology and Hepatology 25, no. 9 (February 3, 2010): 1498–506. http://dx.doi.org/10.1111/j.1440-1746.2010.06282.x.
Full textTarsetti, Fabio, Giuseppe Tarantino, Piergiorgio Mosca, Emidio Scarpellini, and Giammarco Fava. "[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]." Clinical Management Issues 9, no. 4 (December 22, 2015): 95–100. http://dx.doi.org/10.7175/cmi.v9i4.1202.
Full textYang, Jiezuan, Jiajia Chen, Ping Ye, Linfeng Jin, Wei Wu, Guoping Sheng, and Lan-Juan Li. "HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients." Journal of Translational Medicine 12, no. 1 (2014): 183. http://dx.doi.org/10.1186/1479-5876-12-183.
Full textWang, B., I. Carey, M. Bruce, S. Montague, G. Dusheiko, and K. Agarwal. "HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues." Journal of Viral Hepatitis 25, no. 8 (April 2, 2018): 886–93. http://dx.doi.org/10.1111/jvh.12889.
Full textIchida, F., A. Yoshikawa, A. Yachi, Y. Goto, S. Furuta, N. Hattori, S. Kakumu, et al. "Treatment of HBeAg-Positive Chronic Hepatitis with a Streptococcal Preparation (OK-432)." Journal of International Medical Research 13, no. 1 (January 1985): 59–67. http://dx.doi.org/10.1177/030006058501300109.
Full textParfieniuk-Kowerda, Anna, Kamil Grubczak, Andrzej Eljaszewicz, Magdalena Świderska, Magdalena Maciaszek, Anatol Panasiuk, Jerzy Jaroszewicz, Robert Flisiak, and Marcin Moniuszko. "High CD163 Expression on Classical Monocytes Is Associated with Immune Control of HBV Infection in Noncirrhotic Patients." Mediators of Inflammation 2020 (March 29, 2020): 1–13. http://dx.doi.org/10.1155/2020/6364258.
Full textLiaw, Y. F., S. M. Lin, I. S. Sheen, and C. M. Chu. "Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination." Infection 19, no. 4 (July 1991): 250–51. http://dx.doi.org/10.1007/bf01644957.
Full textChen, Zhe, Xiao Ma, Yanling Zhao, Jiabo Wang, Yaming Zhang, Yun Zhu, Lifu Wang, et al. "Kushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis." Evidence-Based Complementary and Alternative Medicine 2015 (2015): 1–12. http://dx.doi.org/10.1155/2015/529636.
Full textLim, Seng-Gee. "CS1-02 The Roleof HBV Viral Quasispeciesin HBeAg Seroconversion." International Journal of Infectious Diseases 13 (August 2009): S3—S4. http://dx.doi.org/10.1016/s1201-9712(09)60248-4.
Full textLiem, Kin Seng, Scott Fung, David K. Wong, Colina Yim, Seham Noureldin, Jiayun Chen, Jordan J. Feld, Bettina E. Hansen, and Harry L. A. Janssen. "Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)." Gut 68, no. 12 (August 28, 2019): 2206–13. http://dx.doi.org/10.1136/gutjnl-2019-318981.
Full textBenias, Petros C., and Albert D. Min. "Goals of Antiviral Therapy for Hepatitis B: HBeAg Seroconversion, HBsAg Seroconversion, Histologic Improvement, and Possible Impact on Risk of Hepatocellular Carcinoma." Current Hepatitis Reports 10, no. 4 (September 8, 2011): 292–96. http://dx.doi.org/10.1007/s11901-011-0112-4.
Full textFung, J., C. L. Lai, D. K. H. Wong, J. Yuen, and M. F. Yuen. "359 INCREASE RISK OF HBeAg-NEGATIVE CHRONIC HEPATITIS B WITH OLDER AGE AT HBeAg SEROCONVERSION." Journal of Hepatology 50 (April 2009): S137. http://dx.doi.org/10.1016/s0168-8278(09)60361-5.
Full textYe, Zhen, Min Zhao, He Jiao, Yang Feng, Ying-zi Li, Cui-fang Nie, Yan-mei Zhang, et al. "Meta-analysis on Treatment of Chronic Hepatitis B with Telbivudine and Entecavir." Infection International 1, no. 4 (December 1, 2012): 216–23. http://dx.doi.org/10.1515/ii-2017-0031.
Full textSacchi, Viola. "Entecavir (Baraclude) in patients with chronic hepatitis B virus (HPV) infection." Farmeconomia. Health economics and therapeutic pathways 9, no. 3 (September 15, 2008): 157–61. http://dx.doi.org/10.7175/fe.v9i3.228.
Full textSacchi, Viola. "Telbivudine (Sebivo) in patients with hepatitis B virus (HBV) chronic infection." Farmeconomia. Health economics and therapeutic pathways 9, no. 4 (January 15, 2008): 215–18. http://dx.doi.org/10.7175/fe.v9i4.238.
Full textHao, Zhang, Zhu Biqing, Yang Ling, and Zeng Wenting. "The Effectiveness of Antiviral Treatments for Patients with HBeAg-Positive Chronic Hepatitis B: A Bayesian Network Analysis." Canadian Journal of Gastroenterology and Hepatology 2018 (September 12, 2018): 1–9. http://dx.doi.org/10.1155/2018/3576265.
Full textChen, Chien-Hung, Sheng-Nan Lu, Chuan-Mo Lee, Chao-Hung Hung, Jing-Houng Wang, and Tsung-Hui Hu. "Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion." Hepatology International 8, no. 3 (May 31, 2014): 365–74. http://dx.doi.org/10.1007/s12072-014-9542-8.
Full textIngman, M., B. Lindqvist, and K. Kidd-Ljunggren. "Novel mutation in Hepatitis B virus preventing HBeAg production and resembling primate strains." Journal of General Virology 87, no. 2 (February 1, 2006): 307–10. http://dx.doi.org/10.1099/vir.0.81562-0.
Full textSong, Guangjun, Huiying Rao, Bo Feng, and Lai Wei. "Prediction of spontaneous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients during the immune clearance phase." Journal of Medical Virology 86, no. 11 (August 2, 2014): 1838–44. http://dx.doi.org/10.1002/jmv.24032.
Full textKim, Hyoung Su, Ha Jung Kim, Woon Geon Shin, Kyung Ho Kim, Jin Heon Lee, Hak Yang Kim, and Myoung Kuk Jang. "Predictive Factors for Early HBeAg Seroconversion in Acute Exacerbation of Patients With HBeAg-Positive Chronic Hepatitis B." Gastroenterology 136, no. 2 (February 2009): 505–12. http://dx.doi.org/10.1053/j.gastro.2008.10.089.
Full textTseng, Yu-Ru, Jia-Feng Wu, Yen-Hsuan Ni, Huey-Ling Chen, Chih-Cheng Chen, Wan-Hsin Wen, Hong-Yuan Hsu, and Mei-Hwei Chang. "Long-term effect of maternal HBeAg on delayed HBeAg seroconversion in offspring with chronic hepatitis B infection." Liver International 31, no. 9 (June 28, 2011): 1373–80. http://dx.doi.org/10.1111/j.1478-3231.2011.02574.x.
Full textBudzinska, Magdalena Agnieszka, Nicholas Adam Shackel, Stephan Urban, and Thomas Tu. "Sequence analysis of integrated hepatitis B virus DNA during HBeAg-seroconversion." Emerging Microbes & Infections 7, no. 1 (August 8, 2018): 1–12. http://dx.doi.org/10.1038/s41426-018-0145-7.
Full textWong, D., M. Littlejohn, L. Yuen, K. Jackson, H. Mason, A. Gaggar, K. Kitrinos, et al. "On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB." Journal of Hepatology 66, no. 1 (2017): S259—S260. http://dx.doi.org/10.1016/s0168-8278(17)30829-2.
Full textZhu, Xiao-Jun, Xue-Hua Sun, Zheng-Hua Zhou, Shun-Qing Liu, Hua Lv, Man Li, Lu Li, and Yue-Qiu Gao. "Lingmao Formula Combined with Entecavir for HBeAg-Positive Chronic Hepatitis B Patients with Mildly Elevated Alanine Aminotransferase: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial." Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–7. http://dx.doi.org/10.1155/2013/620230.
Full textHeathcote, Jenny, George Germanidis, Geoffrey M. Dusheiko, Ira M. Jacobson, Robert A. De Man, Paul Nikolaidis, Patrick Marcellin, et al. "M1782 Characteristics of HBeAg-Positive Patients with HBsAg Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF)." Gastroenterology 136, no. 5 (May 2009): A—837. http://dx.doi.org/10.1016/s0016-5085(09)63856-7.
Full textHeathcote, E. J., G. Germanidis, G. Dusheiko, I. Jacobson, R. deMan, P. Nikolaidis, P. Marcellin, et al. "909 CHARACTERISTICS OF HBeAg-POSITIVE PATIENTS WITH HBsAg LOSS/SEROCONVERSION FOLLOWING TREATMENT WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)." Journal of Hepatology 50 (April 2009): S330. http://dx.doi.org/10.1016/s0168-8278(09)60911-9.
Full textYang, Shih-Cheng, Sheng-Nan Lu, Chuan-Mo Lee, Tsung-Hui Hu, Jing-Houng Wang, Chao-Hung Hung, Chi-Sin Changchien, and Chien-Hung Chen. "Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion." Hepatology International 7, no. 2 (June 22, 2012): 489–99. http://dx.doi.org/10.1007/s12072-012-9382-3.
Full textYao, Chih-Chien, Chuan-Mo Lee, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Sheng-Nan Lu, Chi-Sin Changchien, Mei-Chin Hsu, and Chien-Hung Chen. "Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion." Journal of Gastroenterology and Hepatology 30, no. 5 (April 10, 2015): 918–24. http://dx.doi.org/10.1111/jgh.12874.
Full textMatthews, Gail V., Rachel J. Ali, Anchalee Avihingsanon, Janaki Amin, Rachel Hammond, Scott Bowden, Sharon R. Lewin, et al. "Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals." PLoS ONE 8, no. 4 (April 9, 2013): e61297. http://dx.doi.org/10.1371/journal.pone.0061297.
Full textLau, George K. K. "Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion." Liver International 30, no. 4 (April 2010): 512–20. http://dx.doi.org/10.1111/j.1478-3231.2009.02198.x.
Full textChen, Chien-Hung, Chuan-Mo Lee, Jing-Houng Wang, Tsung-Hui Hu, Chao-Hung Hung, Chi-Sin Changchien, and Sheng-Nan Lu. "Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion." Hepatology International 7, no. 2 (June 21, 2012): 477–88. http://dx.doi.org/10.1007/s12072-012-9381-4.
Full textLin, Chunjing, Hai Zou, and Shumin Wang. "Hepatitis B e Antigen Seroconversion Is Related with the Function of Dendritic Cells in Chronic Hepatitis B Virus Infection." Gastroenterology Research and Practice 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/413952.
Full textNoguchi, Akinori, Jun Hayashi, Koya Nakashima, Miki Hirata, Hideyuki Ikematsu, and Seizaburo Kashiwagi. "HBsAg subtypes among HBsAg carriers in Okinawa, Japan. Evidence of an important relationship in seroconversion from HBeAg to anti-HBe." Journal of Infection 28, no. 2 (March 1994): 141–50. http://dx.doi.org/10.1016/s0163-4453(94)95560-3.
Full textFan, Rong, Jie Peng, Qing Xie, Deming Tan, Min Xu, Junqi Niu, Hao Wang, et al. "Combining Hepatitis B Virus RNA and Hepatitis B Core–Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen–Positive Patients With Chronic Hepatitis B." Journal of Infectious Diseases 222, no. 4 (March 25, 2020): 611–18. http://dx.doi.org/10.1093/infdis/jiaa136.
Full textMurata, Kazumoto. "Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection." World Journal of Gastroenterology 11, no. 43 (2005): 6848. http://dx.doi.org/10.3748/wjg.v11.i43.6848.
Full textWarner, B. G., W. G. H. Abbott, and A. G. Rodrigo. "Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection." Evolution, Medicine, and Public Health 2014, no. 1 (December 13, 2013): 1–9. http://dx.doi.org/10.1093/emph/eot023.
Full textCho, S. "Effect of virologic response on posttreatment durability of lamivudine-induced HBeAg seroconversion." Journal of Hepatology 34 (April 2001): 172. http://dx.doi.org/10.1016/s0168-8278(01)80631-0.
Full textCho, S. W., K. M. Lee, K. B. Hahm, J. H. Kim, K. H. Ko, and H. J. Kim. "Effect of virologic response on posttreatment durability of lamivudine-induced HBeAg seroconversion." Journal of Hepatology 34 (April 2001): 172. http://dx.doi.org/10.1016/s0168-8278(01)81506-3.
Full text